AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
SY

So-Young International Inc. American Depository Shares (SY) fair value

Healthcare · Health Information Services · NASDAQ · United States
$2.11-0.94%
Market cap $214MNext earnings 2026-11-16Updated Oct 24, 2026
Add earnings to calendarGoogle
Our verdict
Trades 73% below our fair value
Price
$2.11
Model fair valueConfidence: low
about $7.69
Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionSo-Young International Inc. American Depository Shares (SY)
Fair value
Not available
ACCE price target
$2.60
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $2.11 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
48
out of 100
Analysts
100% buy
2 covering
P/E
0.0x
forward 16.3x
1-year return
-30.4%
Dividend yield
0.00%

So-Young International Inc. American Depository Shares in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

So-Young International runs China's largest online platform for cosmetic and aesthetic medical procedures, connecting consumers with licensed clinics and surgeons and monetising through advertising, transaction fees and its consumer-facing content and reviews. The structural case rests on the aesthetic medicine market's shift toward online discovery and booking, where So-Young's brand and review base give it a traffic advantage over smaller rivals, and on a gross margin of 46.0% that suggests its marketplace model is pricing reasonably well. Revenue grew 45.6% over the last year, and the stock trades on a forward P/E of 16.3, a sharp contrast with an operating margin of -13.4% and an ROE of -15.0%, so the multiple is only meaningful if the company converts that top-line momentum into operating profit. The near-term question is whether operating losses narrow as revenue scales, which is the single variable a deeper look should test. At a market cap of $235M and no index membership, the name sits in a thin-coverage corner of the market, where a turn in profitability could reprice the stock quickly in either direction. The composite score of 53/100 signals a mixed profile rather than a clear screen pass, so the work ahead is to separate durable growth from growth bought with losses.

AI-assisted·How I use AIWritten Oct 18, 2026

Next results

Nov 16, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where SY's valuation models land
Price
$2.11
Model fair valueConfidence: low
about $7.69
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish100% buy · 2 covering analysts
● Strong buy 2● Buy 0● Hold 0● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-7.0%
1 month
-25.7%
3 months
+9.3%
6 months
-22.4%
YTD
-17.6%
1 year
-30.4%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
15 Oct 2026, 00:00 CESTACCE price target$2.60first publication$2.65

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full SY page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth76Value54Quality43Momentum17Total48
Valuation
Trailing P/E
0.0x
Forward P/E
16.3x
PEG
no data
P/B
1.31x
EV / Revenue
0.8x
Book value/sh
¥2.23
Enterprise value
$225M
Profitability
ROE
-15.0%
FCF yield
-21.13%
ROIC
-10.4%
Health and risk
Debt / equity
0.19
Dividend yield
0.00%
Beta
2.05

Price

-29.2% · 1Y

Ask anything about SY

Answered from So-Young International Inc. American Depository Shares fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 45.8x
ROEbetter than 17% of peers
low -29%-15%high 26%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 12.1%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
SY So-Young International Inc. American Depository Shares$2.11----15.0%4348
SPOK Spok Holdings Inc. Common Stock$10.30$1217% below18.8x8.4%7548
ASCN.SW Ascom Holding AGCHF 5.72CHF 720% below11.0x25.7%7873
AMWL American Well Corporation Class A Common Stock$13.57----29.1%4342
CARA.ST Carasent AB (publ)kr 27.00kr 1584% above45.8x4.8%6658
OPRX OptimizeRx Corporation Common Stock$9.15$93% below38.1x3.7%5451
SUS.ST Surgical Science Sweden AB (publ)kr 57.20kr 562% above31.4x2.1%7063

Sector report card

Where SY ranks against its sector peers on each metric.

Computing percentiles…
  • PR Newswire•Aug 31, 2026
    So-Young Reports Unaudited Second Quarter 2026 Financial Results
  • PR Newswire•Aug 19, 2026
    So-Young to Report Second Quarter 2026 Financial Results on August 31, 2026
  • PR Newswire•Aug 4, 2026
    So-Young Announces Appointment of Chief Financial Officer
3 more press releases · full archive on Investor+.INVESTOR
13 filings of 36
September 2026
Sep 8
Form 4Insider transactionPeriod 2026-09-07
View on SEC →
Sep 8
Form 4Insider transactionPeriod 2026-09-07
View on SEC →
August 2026
Aug 31
6-KForeign current reportPeriod 2026-08-31
View on SEC →
10 more filings + AI summaries on Investor+.INVESTOR